SCHEMBL21639552

SCHEMBL21639552

CNc1cccc2cc(C(=O)Nc3cccc(=O)[nH]3)c(=O)[nH]c12

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.39
KCNH2 Q12809 2/20 0.39
CNR2 P34972 1/20 0.38
KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23066443 0.83 NSD2 (0.50)
SCHEMBL21639618 0.80 LCK (0.41) BRD4KCNH2KDR
SCHEMBL21639564 0.80 MAOA (0.50) KCNH2
SCHEMBL21674050 0.79 BRD4 (0.46) BRD4
SCHEMBL21639472 0.79 BRD4 (0.46) BRD4KCNH2CNR2
SCHEMBL21639644 0.78 CA12 (0.48) KCNH2
SCHEMBL21639490 0.78 NR1H4 (0.58)
SCHEMBL21639509 0.77 TSHR (0.52)
SCHEMBL21639501 0.77 RAB9A (0.51)
SCHEMBL21639635 0.77 DYRK1A (0.41) KCNH2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210070747-A1 2(1H)-QUINOLINONE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-03-11 US disclosed
US-20210070747-A1 2(1H)-QUINOLINONE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2021-03-11 US disclosed
EP-3604281-A1 2(1H)-QUINOLINONE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070747-A1 2(1H)-QUINOLINONE DERIVATIVE TOP2A, TOP2B, TOP1 BRD4 560/4885KCNH2 3730/4885CNR2 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.